VIJAYA DIAGNOSTIC share price has zoomed 8% and is presently trading at Rs 1,109.8.
Meanwhile, the BSE HEALTHCARE index is at 43,965.0 (down 0.3%).
Among the top gainers in the BSE HEALTHCARE index today are Abbott India (up 1.1%) and NARAYANA HRUDAYALAYA (up 1.0%).
ALEMBIC PHARMA (down 3.1%) and AJANTA PHARMA (down 2.3%) are among the top losers today.
Over the last one year, VIJAYA DIAGNOSTIC has moved up from Rs 585.5 to Rs 1,109.8, registering a gain of Rs 524.3 (up 89.5%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,089.2 to 43,965.0, registering a gain of 56.5% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 209.0%), SUVEN PHARMACEUTICALS (up 123.8%) and Glenmark Pharma (up 119.3%).
Don't Miss: Key Information for Long-term Investors
The BSE Sensex is at 79,353.0 (down 0.2%).
The top losers among the BSE Sensex today are Asian Paints (down 2.6%) and ICICI Bank (down 1.9%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.
In the meantime, NSE Nifty is at 24,119.5 (down 0.3%). Asian Paints and Coal India are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 64,958.7 to 79,353.0, registering a gain of 14,394.3 points (up 22.2%).
VIJAYA DIAGNOSTIC net profit grew 25.5% YoY to Rs 421 million for the quarter ended September 2024, compared to a profit of Rs 336 million a year ago. Net sales rose 31.8% to Rs 1,829 million during the period as against Rs 1,389 million in July-September 2023.
For the year ended March 2024, VIJAYA DIAGNOSTIC reported 40.4% increase in net profit to Rs 1,196 million compared to net profit of Rs 852 million during FY23. Revenue of the company grew 19.3% to Rs 5,478 million during FY24.
The current Price to earnings ratio of VIJAYA DIAGNOSTIC, based on rolling 12 month earnings, stands at 85.4.
Equitymaster requests your view! Post a comment on "VIJAYA DIAGNOSTIC Gains 8%; BSE HEALTHCARE Index Down 0.3%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!